

IASCR 2011 Survey of ESCRO Committees: Overview









In September 2011, the Interstate Alliance on Stem Cell Research in conjunction with national partners conducted a brief informal survey to learn more about the current status of ESCRO/SCRO Committees. The survey was designed as a tool to inform the development of an ESCRO workshop at the 2011 World Stem Cell Summit. Based on this intended use, we indicated to respondents:

This [survey] is not considered academic research or comprehensive in anyway.

We added this disclaimer because we did not incorporate procedures that would enable us to quality check the responses (e.g. we were not able to confirm only one response per institution).

Despite the limitations inherent to this survey, we feel the data provides a useful “snapshot” of ESCRO activities at the responding institutions in September 2011. Of note, several institutions indicated at the October summit that they were considering policy changes which would alter some responses. The summary data follow. Note that respondents could skip questions, so the number of responses varies by question.

The institutions responding self-identified as the following:

2. What category best describes you institution or affiliation:		 Create Chart	 Download
		Response Percent	Response Count
Hospital		7.4%	2
Independent IRB or ESCRO		7.4%	2
Private-sector company		3.7%	1
Research Foundation / Institute (not University affiliated)		3.7%	1
Research University		14.8%	4
Research University & Medical School		63.0%	17
		Other (please specify) Show Responses	3
		answered question	27
		skipped question	3

Response numbers by state are the following:

CA n=15, MA n=3, CT n=2, MD, MO, FL, PA, OR, WI, WA, NY

For additional information contact: glomax@cirm.ca.gov

2011 Survey of ESCRO Committees







1. For what types of hESC research / studies does your ESCRO have oversight responsibilities? (check all the apply)

		Response Percent	Response Count
Approving the derivation of hESC lines		96.6%	28
Reviewing the provenance of all hESC lines		72.4%	21
Reviewing the provenance of only non-NIH registered lines		34.5%	10
Registering or tracking in-vitro use of hESC lines without formal protocol review or approval		37.9%	11
Approving protocols for in-vitro use of hESC lines		89.7%	26
Approving the transplantation of hESC lines to animals		100.0%	29
Use of cell lines or cell products differentiated from hESCs		72.4%	21
	Other (please specify)		4
		answered question	29
		skipped question	1




2. For what types of iPSC research / studies does your ESCRO have oversight responsibilities? (check all the apply)

		Response Percent	Response Count
Approving the derivation or creation of iPSCs from cells and/or tissue		69.2%	18
Approving the use of previously derived iPSC lines		73.1%	19
Approving the transplantation of iPSC lines to animals		96.2%	25
	Other (please specify)		8
		answered question	26
		skipped question	4






3. Estimate the total number of protocols requiring ESCRO action in the past 12 months. This includes protocols requiring full review, administrative review, or renewal.

		Response Percent	Response Count
0		0.0%	0
1-5		26.7%	8
6-15		23.3%	7
16-30		20.0%	6
>31		30.0%	9
answered question			30
skipped question			0

4. How many open protocols to derive hESCs does your institution have?

		Response Percent	Response Count
0		33.3%	10
1-5		43.3%	13
Greater than 5		23.3%	7
answered question			30
skipped question			0



7. For research subject to ESCRO oversight, please identify the sources of funding (check all that apply)

		Response Percent	Response Count
Federal NIH		86.2%	25
Other Federal (non-NIH)		44.8%	13
State		75.9%	22
Foundation		75.9%	22
Private Donations		69.0%	20
	Other (please specify)		7
		answered question	29
		skipped question	1




8. Check the statement that best describes the relationship between your ESCRO and IRB

		Response Percent	Response Count
The ESCRO and IRB are completely separate (no interaction during protocol review)		48.1%	13
The ESCRO and IRB meet separately but they share common members who provide expertise on pluripotent / stem cell research		37.0%	10
The ESCRO and IRB are separate but they may hold joint meeting to review pluripotent / stem cell research		3.7%	1
The ESCRO and IRB is the same committee		11.1%	3
	Other (please specify)		6
		answered question	27
		skipped question	3



9. The National Academies' Guidelines for Human Embryonic Stem Cell Research and state polices recommend or require ESCRO committees to perform specified review and oversight functions. What statement best describes your organizations approach to ESCRO development and operations?

		Response Percent	Response Count
ESCRO responsibilities should be limited to those review and oversight functions described in the NAS Guidelines and / or state requirements.		42.9%	12
ESCRO review and oversight responsibilities should evolve as the field of pluripotent stem cell research develops. We have or are considering responsibilities beyond those described in the NAS Guidelines and / or state requirements.		57.1%	16
The ESCRO is being phased down or out as the field has developed.		0.0%	0
	Other (please specify)		1
		answered question	28
		skipped question	2



10. Is or do you foresee your ESCRO being involved in the review of clinical trials involving the use therapeutics derived from human pluripotent stem cells?

		Response Percent	Response Count
Yes		63.0%	17
No		18.5%	5
Not known at this time		18.5%	5
		answered question	27
		skipped question	3







11. If you foresee your ESCRO being involved in the review of clinical trials involving the use therapeutics derived from human pluripotent stem cells, please described the ESCRO role:

		Response Percent	Response Count
ESCRO to provide independent review and approval of certain trials		72.2%	13
ESCRO to perform an advisory role to the IRB or other review body		33.3%	6
	Other (please specify)		2
		answered question	18
		skipped question	12



12. Is your institution currently conducting a clinical trial using therapeutics derived from human pluripotent stem cells?

		Response Percent	Response Count
yes		25.0%	7
no		75.0%	21
		answered question	28
		skipped question	2

14. What category best describes your institution or affiliation:

		Response Percent	Response Count
Hospital		7.4%	2
Independent IRB or ESCRO		7.4%	2
Private-sector company		3.7%	1
Research Foundation / Institute (not University affiliated)		3.7%	1
Research University		14.8%	4
Research University & Medical School		63.0%	17
	Other (please specify)		3
		answered question	27
		skipped question	3

15. Will you be attending the World Stem Cell Summit?

		Response Percent	Response Count
yes		46.4%	13
no		53.6%	15
answered question			28
skipped question			2